Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity. - Wikidata - wikimedia - TriplyDB

Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity.

Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity.

http://www.wikidata.org/entity/Q37701724

about

The utility of 68Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors.

P2860

Q47731752-9783BFB5-A491-4A4B-9AA8-3843A184873A

P2860

Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity.

http://www.wikidata.org/entity/Q37701724

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 October 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Survival prediction in patient ...... statin-receptor heterogeneity.

@en

Survival prediction in patient ...... statin-receptor heterogeneity.

@nl

type

label

Survival prediction in patient ...... statin-receptor heterogeneity.

@en

Survival prediction in patient ...... statin-receptor heterogeneity.

@nl

prefLabel

Survival prediction in patient ...... statin-receptor heterogeneity.

@en

Survival prediction in patient ...... statin-receptor heterogeneity.

@nl

P1433

Q37701724-F972DF07-AC8F-494A-8E8D-C070B5D2CCCA

P1476

Q37701724-18EE1AA7-9379-47FB-93D2-EDE2C8FEFF24

P2093

Q37701724-21C95258-BBF1-43DC-AA81-69C5C6335955

Q37701724-35CAC2AD-97E5-4E20-A445-8C9A77F31121

Q37701724-524B74F7-0342-4ED0-BAA1-E4AC60ABAA35

Q37701724-5C0AD9CC-A420-4F16-9E6B-9A2FD454E16C

Q37701724-6BAB5733-DAF8-4A3D-BC01-0D3A4F034241

Q37701724-87347398-5324-4DE1-8FF0-AA3BFCAE521B

Q37701724-8B8BDC27-5613-4228-A39D-C65D963C7CCD

Q37701724-8D6911FE-537E-416A-92C8-E2D9E116B7A7

Q37701724-BC1F4EA5-1318-41C3-BC82-CE8FFC2A1B1A

Q37701724-DF1471B7-A334-4EF0-8075-4534A10890C3

P2860

Q37701724-01F9E24C-E9FE-471C-A4F3-1F595611F862

Q37701724-035066BF-2C0D-4F1B-9ABC-646FB43BC9EF

Q37701724-14CAA396-60F0-48DC-BAD6-7F8C79D97614

Q37701724-16EAD0EE-9A78-4133-9BDF-7C58EE86C96C

Q37701724-1D7411C9-1E88-4C2D-B424-9F4DC9FE8414

Q37701724-3360372F-CDD4-4F9B-B4F0-66CFAFEFBD6B

Q37701724-33A11DA6-F5DA-492B-820B-9AE3BE5AA6A1

Q37701724-469316F0-6A30-44E3-AB3B-317D5C7B1C98

Q37701724-4A4943AB-A26A-45C0-A580-B8DF6FB5D1CB

Q37701724-4ABA519D-9595-4FB0-86E4-310D1769D82B

P304

Q37701724-A7A05CAD-2644-448A-AE0D-6E566AAA88B2

P31

Q37701724-63A86F16-6F5B-40F8-A9AF-56FF0D83298E

P356

Q37701724-3844E8D8-2908-4305-AB88-CFDC94547261

P407

Q37701724-DA131E70-D0FD-475B-B41A-C50218F0C4C4

P433

Q37701724-EE631DCB-E32B-4676-8FD6-1D55703E0D2D

P478

Q37701724-C3C4745E-4216-44B1-BD7D-E130FC410AF0

P50

Q37701724-69CB5014-90B8-42BF-A505-B0AB332891DD

Q37701724-A2BB4EF0-23C9-418F-BFC4-5063F8238E01

P577

Q37701724-F28EAD8E-B340-4E3C-AC85-32E9F1D5939C

P698

Q37701724-B932B93C-408E-45A9-A172-F4F7599CEB86

P932

Q37701724-CFDE1F14-1443-45F6-A05C-39B9A8AC54B4

P356

ONCOTARGET.12402

P1433

P1476

Survival prediction in patient ...... ostatin-receptor heterogeneity

@en

P2093

Andreas K Buck

http://www.w3.org/2001/XMLSchema#string

Constantin Lapa

http://www.w3.org/2001/XMLSchema#string

Dirk O Muegge

http://www.w3.org/2001/XMLSchema#string

Frank Bengel

http://www.w3.org/2001/XMLSchema#string

Harun Ilhan

http://www.w3.org/2001/XMLSchema#string

Imke Schatka

http://www.w3.org/2001/XMLSchema#string

Markus Essler

http://www.w3.org/2001/XMLSchema#string

Norbert Zsótér

http://www.w3.org/2001/XMLSchema#string

Peter Bartenstein

http://www.w3.org/2001/XMLSchema#string

Ralph A Bundschuh

http://www.w3.org/2001/XMLSchema#string

P2860

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?

Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer

18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort.

Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.

DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6.

In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma.

Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms.

68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis.

P304

7039-7049

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.12402

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Takahiro Higuchi

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27705948

http://www.w3.org/2001/XMLSchema#string

P932

5351689

http://www.w3.org/2001/XMLSchema#string